Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This Special Issue of Cancers (Basel) is mainly dedicated to selecting papers from the talks given during the first Joint Meeting on Lung Cancer (JMLC) between the MD Anderson Cancer Center (Houston, Texas USA) and the Hospital University Federation (HUF) OncoAge (University Côte d’Azur, Nice, France) (Nice, September 2018). The central theme of JMLC is to discuss new advances and exchange ideas regarding lung cancer. Notably, the talks covered different topics on new therapeutic strategies (targeted therapy and immuno-oncology), molecular and cellular biology, biomarkers, and the epidemiology of lung cancer. Special attention was also given to lung cancer in elderly patients. The articles published in this Special Issue covered subjects such as the assessment of new biomarkers and new approaches for the early detection of lung cancer, epidemiological data, and emphasized a place for the newly characterized cellular pathways in lung cancer, which opens room for therapeutic perspectives for lung cancer patients.

microRNAs --- multiplexed --- screening --- education --- non-smoker --- image analysis --- artificial intelligence --- research --- lung cancer --- spatial analysis --- optimization --- fluorescence --- geriatric assessment --- geriatric interventions --- TNBC --- liquid biopsy --- non-small cell lung cancer --- integrated approaches --- well-being --- hormone-like action --- EGFR mutations --- reversal of EMT --- tumor plasticity --- immune profiling --- macrophage --- multiplexed methodologies --- targeted treatment --- techniques --- immune-oncology --- bioinformatics --- MALAT1 --- long non-coding RNAs --- CD8 T Cells --- personal medicine --- EGFR TKIs --- lncRNA --- hormones --- elderly --- interleukin-1? and immunometabolism --- chromogenic --- xenograft --- metastasis --- PD-1/PD-L1 checkpoint blockade --- immunotherapy --- molecular --- cancer tissues --- digital --- NSCLC --- immune blockade --- lung adenocarcinoma --- circulating tumor cells --- brightfield --- non-coding RNAs --- older adults --- cancer --- tumor microenvironment --- aging --- rational therapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This Special Issue of Cancers focuses on new advances in the treatment of renal cell carcinoma, both surgical and pharmacological (and combinations of these), and novel approaches to tackle treatment resistance and improve our understanding of this phenomenon.

Medicine --- renal cell carcinoma --- autophagy --- hydroxychloroquine --- chloroquine --- ROC-325 --- cysteine cathepsins --- cysteine cathepsin inhibitors --- lysosome --- renal cancer --- metastatic renal cell carcinoma --- immune-based combination therapies --- network meta-analysis --- PD-L1 --- predictive --- biomarker --- treatment --- TKIs --- mRCC --- biomarkers --- soluble factors --- immunotherapy --- renal cell carcinoma (RCC) --- sunitib resistance --- artesunate (ART) --- Traditional Chinese Medicine (TCM) --- growth inhibition --- ferroptosis --- reactive oxygen species (ROS) --- clear cell renal cell carcinoma --- ccRCC --- RCC --- kidney cancer --- evolution --- evolutionary trajectory --- metastatic --- second line therapy --- renal cell cancer --- immune checkpoint inhibitors --- tyrosine kinase inhibitors --- individualization --- genomic signature --- transcriptomic analysis --- renal cell carcinoma --- autophagy --- hydroxychloroquine --- chloroquine --- ROC-325 --- cysteine cathepsins --- cysteine cathepsin inhibitors --- lysosome --- renal cancer --- metastatic renal cell carcinoma --- immune-based combination therapies --- network meta-analysis --- PD-L1 --- predictive --- biomarker --- treatment --- TKIs --- mRCC --- biomarkers --- soluble factors --- immunotherapy --- renal cell carcinoma (RCC) --- sunitib resistance --- artesunate (ART) --- Traditional Chinese Medicine (TCM) --- growth inhibition --- ferroptosis --- reactive oxygen species (ROS) --- clear cell renal cell carcinoma --- ccRCC --- RCC --- kidney cancer --- evolution --- evolutionary trajectory --- metastatic --- second line therapy --- renal cell cancer --- immune checkpoint inhibitors --- tyrosine kinase inhibitors --- individualization --- genomic signature --- transcriptomic analysis